Biofidelity launches new website ahead of commercialisation of ASPYRE-Lung

Cambridge, UK 11 February 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces the launch of its new website as the company works towards the commercialization of its first product, ASPYRE-Lung, a comprehensive lung cancer diagnostic panel that enables fast, simple and ultra-sensitive detection of DNA and RNA markers from both tissue and liquid biopsies using existing laboratory instrumentation.

The past year has been transformational for Biofidelity as we expand our team and harness our revolutionary technology to develop and launch our first product. As we move into this new phase for the company, we wanted a website to reflect our scientific and cancer diagnostic expertise in a user-friendly format, with improved navigation and functionality that allows our customers and partners to see not only our first product, ASPYRE-Lung, but also the possibilities of how we can work together to advance cancer diagnostics. Biofidelity is revolutionizing cancer diagnostics by removing the barriers that prevent most patients from accessing world class precision testing. Biofidelity’s diagnostic panels will mean all cancer patients should be able to receive the right treatment at the right time, based on best-in-class information.
Dr. Barnaby Balmforth
Chief Executive Officer of Biofidelity

As we move towards the launch of our first product ASPYRE-Lung, a simple, but comprehensive lung cancer diagnostic panel, we are focused on engaging with both laboratories who are looking to provide superior diagnostics and clinicians who understand how our product can benefit their patients. We understand the need for precision and speed. ASPYRE-Lung can provide actionable information in hours rather than days. Our cancer diagnostic panels will enable clinicians to make optimal treatment decisions, not only for initial diagnosis but also to detect when a cancer has recurred or a patient has become resistant to therapy. Biofidelity’s products have the potential to advance the cancer diagnostic landscape in a way which will benefit all those vested in treating cancer quickly, accurately and cost effectively.
Stephen Miller
Chief Commercial Officer of Biofidelity

Our new website is designed by KISS Communications.